Literature DB >> 10592104

Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy.

Y Ninomiya1, A Yanagisawa, Y Kato, T Kitagawa, S Ishihara, T Nakajima.   

Abstract

PURPOSE: Although preoperative chemotherapy for advanced gastric cancer is now commonly applied with favorable results, convincing evidence for life prolongation and predictive markers for a good prognosis are both lacking. We report here 5 cases that have shown a distinct positive effect of preoperative chemotherapy together with the results of a precise histological examination of materials indicating features predicting a favorable outcome. PATIENTS AND METHODS: A total of 18 patients with a far-advanced gastric carcinoma subjected to gastrectomy after FLEP (5-fluorouracil, leucovorin, etoposide, cisplatin) in the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, could be divided into two distinct groups: 5 surviving over 5 years (group A) and 13 who died within 13 months (group B). Histological features (subtypes) of the carcinomas and chemotherapeutic effects were studied with reference to biopsy materials and resected stomachs and lymph nodes.
RESULTS: In group A, 3 of 5 patients had solid-type poorly differentiated adenocarcinomas. In contrast, in group B, 9 had tubular adenocarcinomas (well or moderately differentiated) and 3 non-solid or diffuse-type poorly differentiated adenocarcinomas and there was only one solid-type tumor. In group A, remarkable therapeutic effects were apparent histologically in 4 of the 5 patients with almost complete disappearance of cancer cells from metastases in lymph nodes, whereas no such changes were evident in group B.
CONCLUSION: FLEP is distinctly beneficial for certain types of advanced gastric carcinoma, especially solid-type poorly differentiated adenocarcinomas, and favorable results can be predicted, to a certain extent, on the basis of findings for the material resected after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10592104     DOI: 10.1007/s004320050337

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  11 in total

1.  An application study of low-dose computed tomography perfusion imaging for evaluation of the efficacy of neoadjuvant chemotherapy for advanced gastric adenocarcinoma.

Authors:  Zongqiong Sun; Xiaofang Cheng; Yuxi Ge; Lin Shao; Yinghua Xuan; Gen Yan
Journal:  Gastric Cancer       Date:  2017-09-04       Impact factor: 7.370

Review 2.  Proteomic and metabolic prediction of response to therapy in gastric cancer.

Authors:  Michaela Aichler; Birgit Luber; Florian Lordick; Axel Walch
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

3.  Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.

Authors:  Zhipeng Sun; Nengwei Zhang
Journal:  World J Surg Oncol       Date:  2014-12-29       Impact factor: 2.754

Review 4.  Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer.

Authors:  Jichun Zhou; Jianguo Shen; Benjamin J Seifer; Shaojie Jiang; Ji Wang; Hanchu Xiong; Lingmin Xie; Linbo Wang; Xinbing Sui
Journal:  Oncotarget       Date:  2017-05-02

5.  Which is the optimal management for locally advanced gastric cancer patients with TRG 0 and 1 after R0 resection?

Authors:  Fei Ma; Yonglei Zhang; Liangqun Peng; Zhandong Zhang; Wei Yang; Junhui Chai; Bin Zhang; Sheqing Ji; Yawei Hua; Xiaobing Chen; Suxia Luo
Journal:  Ann Transl Med       Date:  2020-08

6.  Prediction Model of Tumor Regression Grade for Advanced Gastric Cancer After Preoperative Chemotherapy.

Authors:  Wei Xu; Qianchen Ma; Lingquan Wang; Changyu He; Sheng Lu; Zhentian Ni; Zichen Hua; Zhenglun Zhu; Zhongyin Yang; Yanan Zheng; Runhua Feng; Chao Yan; Chen Li; Xuexin Yao; Mingmin Chen; Wentao Liu; Min Yan; Zhenggang Zhu
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

7.  Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy.

Authors:  Zi-Ning Liu; Yin-Kui Wang; Li Zhang; Yong-Ning Jia; Shan Fei; Xiang-Ji Ying; Yan Zhang; Shuang-Xi Li; Yu Sun; Zi-Yu Li; Jia-Fu Ji
Journal:  World J Gastrointest Oncol       Date:  2021-12-15

8.  New utility of an old marker: serum low-density lipoprotein predicts histopathological response of neoadjuvant chemotherapy in locally advanced gastric cancer.

Authors:  Ji-Chun Zhou; Ju-Feng Guo; Rong-Yue Teng; Qin-Chuan Wang; Ji Wang; Qun Wei; Zi-Duo Li; Jian-Guo Shen; Lin-Bo Wang
Journal:  Onco Targets Ther       Date:  2016-08-12       Impact factor: 4.147

9.  Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI).

Authors:  Hironaga Satake; Akira Miki; Masato Kondo; Takeshi Kotake; Yoshihiro Okita; Yukimasa Hatachi; Hisateru Yasui; Yukihiro Imai; Chihiro Ichikawa; Kenta Murotani; Hiroki Hashida; Hiroyuki Kobayashi; Masahito Kotaka; Takeshi Kato; Satoshi Kaihara; Akihito Tsuji
Journal:  ESMO Open       Date:  2017-03-09

10.  Association of serum levels of deoxyribose 1-phosphate and S-lactoylglutathione with neoadjuvant chemotherapy sensitivity in patients with gastric cancer: A metabolomics study.

Authors:  Daguang Wang; Wei Li; Lei Yin; Yechao Du; Shaopeng Zhang; Jian Suo
Journal:  Oncol Lett       Date:  2020-01-24       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.